Skip to main navigation Skip to search Skip to main content

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 In Adults With Chronic Heart Failure With Reduced Ejection Fraction

Project: Research

Project Details

StatusFinished
Effective start/end date11/30/21 → 12/31/25

Funding

  • Merck Sharp and Dohme Limited Liability Corporation: $250,349.40